Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "FOSAPREPITANT DIMEGLUMINE FOR INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"FOSAPREPITANT DIMEGLUMINE FOR INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company") announces that the "fosaprepitant dimeglumine for injection" (brand name "Shanqi"( 善啟)), a drug used for the prevention of nausea and vomiting caused by chemotherapy, developed by Chia-Tai Tianqing Pharmaceutical Group Co., Ltd, a subsidiary of the Company, has obtained the approval for drug registration granted by the National Drug Administration of the People's Republic of China. The product is registered as a previous Chemicals Category 3.1 drug. The approved indications are: combined with other antiemetics, applicable to the prevention of acute and delayed nausea and vomiting during the initial and repeated treatment of highly vomiting chemotherapy drugs in adult patients.

Fosaprepitant dimeglumine is a neurokinin-1(NK-1) receptor antagonist and a prodrug of aprepitant. It has the characteristics of new mechanism of action, affirmative efficacy, high safety and wide clinical

application. As a drug urgently needed in clinical practice, fosaprepitant dimeglumine has been included in the "List of First Batch of Encouraged Generic Drugs" 《( 第一批鼓勵仿製藥品目錄》) of China.

Currently, the main antiemetic drugs for clinical use in chemotherapy in China are 5-HT3 receptor antagonists. Its antiemetic effect is obvious, but it is difficult to completely and effectively control due to the different severity of vomiting. The emergence of fosaprepitant dimeglumine brings a new era to the treatment of chemotherapy related nausea and vomiting from the so-called"5-HT3 receptor antagonist era", with significant room for market development.

1

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 30 October 2019

As at the date of this announcement, the Board comprises eight Executive Directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

2